Dennis Ding
Stock Analyst at Jefferies
(3.86)
# 1,903
Out of 5,058 analysts
88
Total ratings
50.6%
Success rate
9.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Downgraded: Hold | $36 | $36.34 | -0.94% | 1 | Oct 8, 2026 | |
| ROIV Roivant Sciences | Reiterated: Buy | $42 → $52 | $33.53 | +55.09% | 18 | Sep 8, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $105 | $68.07 | +54.25% | 1 | Sep 8, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $40 | $13.02 | +207.22% | 1 | Jul 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $31.74 | +26.02% | 1 | Jul 6, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $15 | $3.09 | +385.44% | 7 | Jun 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $125 | $86.17 | +45.06% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Reiterated: Buy | $62 | $24.00 | +158.33% | 4 | May 19, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $25.87 | -14.96% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $6.58 | +507.90% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $4.22 | +65.88% | 4 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 → $26 | $20.30 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $32.45 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $19.83 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $18 | $26.73 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.65 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $20.09 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $3.47 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $2.30 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $13.47 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $1.01 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $110.16 | n/a | 4 | Feb 14, 2023 |
Pacira BioSciences
Oct 8, 2026
Downgraded: Hold
Price Target: $36
Current: $36.34
Upside: -0.94%
Roivant Sciences
Sep 8, 2026
Reiterated: Buy
Price Target: $42 → $52
Current: $33.53
Upside: +55.09%
Tarsus Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $105
Current: $68.07
Upside: +54.25%
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $13.02
Upside: +207.22%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $31.74
Upside: +26.02%
Ardelyx
Jun 26, 2026
Reiterated: Buy
Price Target: $15
Current: $3.09
Upside: +385.44%
Rhythm Pharmaceuticals
Jun 15, 2026
Reiterated: Buy
Price Target: $125
Current: $86.17
Upside: +45.06%
SpyGlass Pharma
May 19, 2026
Reiterated: Buy
Price Target: $62
Current: $24.00
Upside: +158.33%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $25.87
Upside: -14.96%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $6.58
Upside: +507.90%
Dec 11, 2025
Reiterated: Buy
Price Target: $7
Current: $4.22
Upside: +65.88%
Sep 3, 2025
Reiterated: Hold
Price Target: $15 → $26
Current: $20.30
Upside: n/a
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $32.45
Upside: n/a
Jun 11, 2025
Reiterated: Buy
Price Target: $45
Current: $19.83
Upside: n/a
May 29, 2025
Reiterated: Hold
Price Target: $20 → $18
Current: $26.73
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $1.65
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $20.09
Upside: n/a
Sep 3, 2024
Reiterated: Hold
Price Target: $8 → $6
Current: $3.47
Upside: n/a
Jul 17, 2024
Reiterated: Hold
Price Target: $1
Current: $2.30
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $13.47
Upside: n/a
Jul 13, 2023
Reiterated: Buy
Price Target: $18
Current: $1.01
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $110.16
Upside: n/a